Research Article

Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects

Table 1

Baseline characteristics of patients.

CharacteristicsTotal
Subgroups value
Low-dose group
High-dose group

Male24 (72.7%)16 (72.7%)8 (72.7%)1
Age, years74 (68–80)75 (63–80)74 (72–80)0.154
Height, cm161 (155–166)162 (155–165)161 (153–166)0.924
Weight, kg57 (50–63)58 (52–64)52 (44–61)0.194
BMI, kg/m222 (18–25)22 (19–25)20 (17–24)0.154
Duration of DKT administration, days12 (7–20)8 (5–15)18 (10–24)0.075
Percentage of dietary intake eaten to fed before DKT administration, %60 (50–90)60 (50–85)70 (50–85)0.671
Time since last bowel movement, days4 (2–6)4 (2–6)5 (3–6)0.714
Concomitant drugs
 Heavy magnesium oxide21 (63.6%)14 (63.6%)7 (63.6%)1
 Senna17 (51.5%)10 (45.5%)7 (36.6%)0.3245
 Opioids4 (12.1%)3 (13.6%)1 (9.0%)0.7061
 Chemotherapy4 (12.1%)2 (9.0%)2 (18.2%)0.4507
Complications
 Parkinson’s disease0 (0%)0 (0%)0 (0%)1
 Cerebral vascular disease5 (15.2%)5 (22.7%)0 (0%)0.0861
 Diabetes8 (24.2%)5 (22.7%)3 (27.3%)0.7739
Laboratory data
 Na (mEq/L)139 (136–141)139 (136–141)141 (138–142)0.273
 K (mEq/L)4.2 (4.0–4.5)4.2 (3.9–4.4)4.4 (4.1–4.5)0.893
 Cl (mEq/L)102 (100–105)103 (99–105)102 (101–104)0.863
 AST (IU/L)20 (18–24)20 (18–24)20 (18–25)0.968
 ALT (IU/L)16 (12–23)18 (12–26)14 (10–18)0.0874
 T-Bil (mg/dL)0.6 (0.4–0.7)0.5 (0.4–0.8)0.6 (0.41–0.7)0.809
 BUN (mg/dL)16 (14–20)17 (14–22)15 (13–16)0.231
 Cre (mg/dL)0.8 (0.6–1.0)0.8 (0.6–1.0)0.9 (0.6–1.0)0.633
 Alb (g/dL)3.4 (3.3–3.7)3.4 (3.3–3.8)3.4 (3.2–3.7)0.901
 BS (mg/dL)112 (97–137)115 (102–137)109 (97–141)1

AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-Bil, total bilirubin; Cre, serum creatinine; BUN, blood urea nitrogen; Alb, albumin; BS, blood sugar; DKT, Daikenchuto.